BUSINESS

Lilly to Continue Investment in Alzheimer’s after Solanezumab Setback: Japan Development Chief

March 16, 2017

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

Eli Lilly is poised to continue its development drive for Alzheimer’s disease (AD) drugs even after it dropped its once-hopeful monoclonal antibody solanezumab for the treatment of mild to moderate AD, the company’s Japan development head said on March 15.…

To read the full story

Lilly Japan Sales Up 7% in 2017, Upbeat Biz Fueled by Global Simultaneous Development
March 23, 2018
Lilly’s Japan Sales Keep Momentum in 2016 with 3.1% Rise
March 16, 2017

BUSINESS

Japan IP High Court Upholds Invalidation of Key Trazenta Dosage Patent
February 19, 2026
ONODERA GT Pharma Targets 2026 Filings for Two Gene Therapies
February 19, 2026
Sumitomo Pharma Sees iPSC Therapy as Potential US$1 Billion Global Product
February 18, 2026
AstraZeneca Launches Japan Registry Study of Imfinzi in Limited-Stage SCLC
February 18, 2026
Asahi Kasei Gets Global Rights to Alchemedicine’s Lead Compounds
February 18, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Is Calling for an Abolition the Right Play? Rethinking Japan’s FY2027 Off-Year Drug Price Revision

By Ken Yoshino

Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…

COLUMN

AI in Healthcare Hiring: Leveling the Playing Field & Unlocking Human Potential

By Philip Carrigan

The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…